# US 6,730,472 B2 · Non-nuclear effects of thyroid hormone

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,730,472 B2
- Document ID: US6730472B2
- Status: Granted
- Kind: B2
- Application number: 09/894,734
- Filed: 2001-06-28
- Published: 2002-07-11
- Granted: 2004-05-04
- Earliest claimed: 2000-06-28
- Assignees: University of Massachusetts
- Inventors: Jack L. Leonard; Alan P. Farwell
- Web page: https://patentgrep.com/patent/US6730472B2

## CPC

- G01N 33/78: Thyroid gland hormones {, e.g. T3, T4, TBH, TBG or their receptors}
- G01N 2500/00: Screening for compounds of potential therapeutic value
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Truncated thyroid hormone receptors ΔTRα1 and ΔTRα2 have been discovered to play a role in actin-based endocytosis, e.g., in the nervous system. The invention relates to methods of discovering ligands effective in modulating endocytosis and transgenic mice with altered expression of ΔTRα1 and ΔTRα2. The invention is useful for the discovery and testing of compounds for treating disorders of the nervous system such as depression.

## Claims

### Claim 1

A method of assaying a translation product of a mutant ΔTRα2 gene, the method comprising
(a) providing a test cell that comprises p29 vesicles and a mutant ΔTRα2 translation product;
(b) contacting the test cell with a labeled ΔTRα2 ligand for a time sufficient to permit binding to the translation product; and
(c) measuring the amount, location, or rate of transit of the ligand in the test cell compared to the amount, location, or rate of transit of the ligand in a control cell that does not comprise a mutant ΔTRα2 translation product.

### Claim 2 (depends on 1)

The method of claim 1, wherein the ligand is a flavone.

### Claim 3 (depends on 1)

The method of claim 1, wherein the ligand is an aurone.

### Claim 4 (depends on 1)

The method of claim 1, wherein the ligand is a T4 analog.

### Claim 5 (depends on 2)

The method of claim 2, wherein the cell is a neuron.

### Claim 6 (depends on 1)

The method of claim 1, wherein the cell is an astrocyte.

### Claim 7 (depends on 1)

The method of claim 1, wherein the amount of the ligand in the cell is measured.

### Claim 8 (depends on 1)

The method of claim 1, wherein the location of the ligand in the cell is measured.

### Claim 9 (depends on 1)

The method of claim 1, wherein the rate of transit of the ligand in the cell is measured.

### Claim 10 (depends on 1)

The method of claim 1, wherein the control cell comprises a wild type ΔTRα2 protein, and a decrease in the amount location, or rate of transit of the ligand in the test cell compared to the control indicates a decrease in the ability of the translation product to transport a vesicle compared to a wild type ΔTRα2 protein.
